218 related articles for article (PubMed ID: 29080225)
21. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation.
De Nunzio C; Kramer G; Marberger M; Montironi R; Nelson W; Schröder F; Sciarra A; Tubaro A
Eur Urol; 2011 Jul; 60(1):106-17. PubMed ID: 21497433
[TBL] [Abstract][Full Text] [Related]
22. Prostatic osteopontin expression is associated with symptomatic benign prostatic hyperplasia.
Popovics P; Awadallah WN; Kohrt SE; Case TC; Miller NL; Ricke EA; Huang W; Ramirez-Solano M; Liu Q; Vezina CM; Matusik RJ; Ricke WA; Grabowska MM
Prostate; 2020 Jul; 80(10):731-741. PubMed ID: 32356572
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic investigations of canine prostatitis incidence together with benign prostate hyperplasia, prostate malignancies, and biochemical recurrence in high-risk prostate cancer as a model for human study.
Shafiee R; Shariat A; Khalili S; Malayeri HZ; Mokarizadeh A; Anissian A; Ahmadi MR; Hosseini E; Naderafif M; Mohsenzadeh S; Rasoulian MH; Rezapour R; Pourzaer M
Tumour Biol; 2015 Apr; 36(4):2437-45. PubMed ID: 25420908
[TBL] [Abstract][Full Text] [Related]
24. PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS.
Vignozzi L; Gacci M; Cellai I; Morelli A; Maneschi E; Comeglio P; Santi R; Filippi S; Sebastianelli A; Nesi G; Serni S; Carini M; Maggi M
Prostate; 2013 Sep; 73(13):1391-402. PubMed ID: 23765639
[TBL] [Abstract][Full Text] [Related]
25. Heme oxygenase levels and metaflammation in benign prostatic hyperplasia patients.
Russo GI; Vanella L; Castelli T; Cimino S; Reale G; Urzì D; Li Volti G; Gacci M; Carini M; Motta F; Caltabiano R; Puzzo L; Sorrenti V; Morgia G
World J Urol; 2016 Aug; 34(8):1183-92. PubMed ID: 26621207
[TBL] [Abstract][Full Text] [Related]
26. Correlation between benign prostatic hyperplasia and inflammation.
Bostanci Y; Kazzazi A; Momtahen S; Laze J; Djavan B
Curr Opin Urol; 2013 Jan; 23(1):5-10. PubMed ID: 23159991
[TBL] [Abstract][Full Text] [Related]
27. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH).
Gandaglia G; Briganti A; Gontero P; Mondaini N; Novara G; Salonia A; Sciarra A; Montorsi F
BJU Int; 2013 Aug; 112(4):432-41. PubMed ID: 23650937
[TBL] [Abstract][Full Text] [Related]
28. The underlying mechanism of metabolic syndrome on benign prostatic hyperplasia and prostate volume.
Xia BW; Zhao SC; Chen ZP; Chen C; Liu TS; Yang F; Yan Y
Prostate; 2020 May; 80(6):481-490. PubMed ID: 32104919
[TBL] [Abstract][Full Text] [Related]
29. Chemokines and BPH/LUTS.
Macoska JA
Differentiation; 2011; 82(4-5):253-60. PubMed ID: 21600689
[TBL] [Abstract][Full Text] [Related]
30. An Asian multinational prospective observational registry of patients with benign prostatic hyperplasia, with a focus on comorbidities, lower urinary tract symptoms and sexual function.
Li MK; Garcia L; Patron N; Moh LC; Sundram M; Leungwattanakij S; Pripatnanont C; Cheng C; Chi-Wai M; Loi-Cheong N
BJU Int; 2008 Jan; 101(2):197-202. PubMed ID: 18005205
[TBL] [Abstract][Full Text] [Related]
31. Distribution of chronic prostatitis in radical prostatectomy specimens with up-regulation of bcl-2 in areas of inflammation.
Gerstenbluth RE; Seftel AD; MacLennan GT; Rao RN; Corty EW; Ferguson K; Resnick MI
J Urol; 2002 May; 167(5):2267-70. PubMed ID: 11956490
[TBL] [Abstract][Full Text] [Related]
32. Effect of Sacral Neuromodulation on Outcome Measures and Urine Chemokines in Interstitial Cystitis/Painful Bladder Syndrome Patients.
Peters KM; Jayabalan N; Bui D; Killinger K; Chancellor M; Tyagi P
Low Urin Tract Symptoms; 2015 May; 7(2):77-83. PubMed ID: 26663686
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical expression of interleukin-2 receptor and interleukin-6 in patients with prostate cancer and benign prostatic hyperplasia: association with asymptomatic inflammatory prostatitis NIH category IV.
Engelhardt PF; Seklehner S; Brustmann H; Lusuardi L; Riedl CR
Scand J Urol; 2015 Apr; 49(2):120-6. PubMed ID: 25363611
[TBL] [Abstract][Full Text] [Related]
34. Association between Benign Prostatic Hyperplasia and Neutrophil-Lymphocyte Ratio, an Indicator of Inflammation and Metabolic Syndrome.
Ozer K; Horsanali MO; Gorgel SN; Horsanali BO; Ozbek E
Urol Int; 2017; 98(4):466-471. PubMed ID: 27464069
[TBL] [Abstract][Full Text] [Related]
35. Inflammatory Responses in a Benign Prostatic Hyperplasia Epithelial Cell Line (BPH-1) Infected with Trichomonas vaginalis.
Kim SS; Kim JH; Han IH; Ahn MH; Ryu JS
Korean J Parasitol; 2016 Apr; 54(2):123-32. PubMed ID: 27180569
[TBL] [Abstract][Full Text] [Related]
36. Relationship between benign prostatic hyperplasia/lower urinary tract symptoms and total serum testosterone level in healthy middle-aged eugonadal men.
Lee JH; Kim Y; Park YW; Lee DG
J Sex Med; 2014 May; 11(5):1309-15. PubMed ID: 24612680
[TBL] [Abstract][Full Text] [Related]
37. Significance of obesity markers and adipocytokines in high grade and high stage prostate cancer in North Indian men - a cross-sectional study.
Tewari R; Rajender S; Natu SM; Goel A; Dalela D; Goel MM; Tondon P
Cytokine; 2013 Aug; 63(2):130-4. PubMed ID: 23669251
[TBL] [Abstract][Full Text] [Related]
38. Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia.
Robert G; Smit F; Hessels D; Jannink S; Karthaus HF; Aalders T; Jansen K; de la Taille A; Mulders PF; Schalken JA
Prostate; 2011 Nov; 71(15):1701-9. PubMed ID: 21446005
[TBL] [Abstract][Full Text] [Related]
39. Intraepithelial lymphocytes in relation to NIH category IV prostatitis in autopsy prostate.
Dikov D; Bachurska S; Staikov D; Sarafian V
Prostate; 2015 Jul; 75(10):1074-84. PubMed ID: 25917232
[TBL] [Abstract][Full Text] [Related]
40. Association of prostatic inflammation with down-regulation of macrophage inhibitory cytokine-1 gene in symptomatic benign prostatic hyperplasia.
Taoka R; Tsukuda F; Ishikawa M; Haba R; Kakehi Y
J Urol; 2004 Jun; 171(6 Pt 1):2330-5. PubMed ID: 15126815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
